4575.TSE · CanBas Co., Ltd

-

Please sign in to comment on 4575.TSE

1 Comment

Admin

4 years ago

CanBas Co., Ltd is currently in a long term downtrend where the price is trading 23.0% below its 200 day moving average.

From a valuation standpoint, the stock is 55.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 31.3.

CanBas Co., Ltd's total revenue rose by 0.0% to $28M since the same quarter in the previous year.

Its net income has increased by 21.6% to $-100M since the same quarter in the previous year.

Based on the above factors, CanBas Co., Ltd gets an overall score of 3/5.

ISIN	JP3244570002
Sector	Healthcare
Industry	Biotechnology
Exchange	TSE
CurrencyCode	JPY

Market Cap	20B
PE Ratio	None
Target Price	None
Beta	-1.11
Dividend Yield	None

ABOUT

CanBas Co., Ltd

CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.

4575.TSE · CanBas Co., Ltd

-

CanBas Co., Ltd

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest CanBas Co., Ltd using a moving average strategy